These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36921901)

  • 21. Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021.
    Trouiller JB; Laramée P
    Med Decis Making; 2023; 43(7-8):961-972. PubMed ID: 37480275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Drug assessment: IQWiG, G-BA, and an international comparison].
    Glaeske G
    Internist (Berl); 2016 Jan; 57(1):94-101. PubMed ID: 26502888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Termination of Reimbursement of Arthroscopy in Osteoarthritis of the Knee: Is This Decision Based on Scientific Grounds?].
    Liebs TR; Berger S
    Z Orthop Unfall; 2017 Aug; 155(4):417-428. PubMed ID: 28675916
    [No Abstract]   [Full Text] [Related]  

  • 24. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions.
    Fischer KE; Stargardt T
    Med Decis Making; 2014 Nov; 34(8):1030-47. PubMed ID: 25149822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence.
    Bullement A; Taylor M; McMordie ST; Waters E; Hatswell AJ
    Pharmacoeconomics; 2019 Nov; 37(11):1383-1390. PubMed ID: 31250397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales.
    Thokala P; Carlson JJ; Drummond M
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1162-1170. PubMed ID: 32857653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia.
    Fischer KE; Heisser T; Stargardt T
    Health Policy; 2016 Oct; 120(10):1115-1122. PubMed ID: 27628196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Requirements for benefit assessment in Germany and England - overview and comparison.
    Ivandic V
    Health Econ Rev; 2014 Dec; 4(1):12. PubMed ID: 26054401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
    Bullement A; Meng Y; Cooper M; Lee D; Harding TL; O'Regan C; Aguiar-Ibanez R
    J Med Econ; 2019 Mar; 22(3):205-214. PubMed ID: 30422080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options.
    Mühlbacher AC; Sadler A
    Value Health; 2017 Feb; 20(2):266-272. PubMed ID: 28237207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decision making by NICE: examining the influences of evidence, process and context.
    Cerri KH; Knapp M; Fernández JL
    Health Econ Policy Law; 2014 Apr; 9(2):119-41. PubMed ID: 23688554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making.
    Tai TA; Latimer NR; Benedict Á; Kiss Z; Nikolaou A
    Value Health; 2021 Apr; 24(4):505-512. PubMed ID: 33840428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Added Therapeutic Value of Medicinal Products for French and German Health Technology Assessment Organizations: A Systematic Comparison.
    Boucaud-Maitre D; Berdaï D; Salvo F
    Value Health; 2021 Mar; 24(3):346-352. PubMed ID: 33641768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
    Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
    Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
    Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
    BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of quality of data submitted for NICE technology appraisals over two decades.
    Osipenko L; Ul-Hasan SA; Winberg D; Prudyus K; Kousta M; Rizoglou A; Rustignoli I; van der Maas L
    BMJ Open; 2024 Feb; 14(2):e074341. PubMed ID: 38351112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree.
    Dintsios CM; Worm F; Ruof J; Herpers M
    Health Econ Rev; 2019 Dec; 9(1):35. PubMed ID: 31848760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [HTA in the decision-making processes of health care institutions. Current state and relevant questions of regulatory health law].
    Francke R; Hart D
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):241-50. PubMed ID: 16482461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.